Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01546987 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 239
- Enrollment target
- 20
- Study locations
NCT01546987 is a Phase 3 study of Prostate Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 239 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT01546987, a Phase 3 study of Prostate Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 239 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer when combined with hormone therapy. Studying quality-of-life in patients having cancer treatment may help identify the intermediate- and long-term effects of treatment on patients with prostate cancer. PURPOSE: This randomized phase III trial is studying the use of hormone therapy, including TAK-700, together with radiation therapy in treating patients with prostate cancer.
Conditions Studied
Interventions
- RADIATION Radiation therapy
- DRUG GnRH agonist
- DRUG Anti-androgen
- DRUG TAK-700
Study Locations (20)
California
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- Mercy San Juan Medical Center - Carmichael
- Veterans Administration Long Beach Medical Center - Long Beach
- Los Angeles County-USC Medical Center - Los Angeles
- University of Southern California/Norris Cancer Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Pomona Valley Hospital Medical Center - Pomona
- Rohnert Park Cancer Center - Rohnert Park
- Sutter Cancer Centers Radiation Oncology Services-Roseville - Roseville
- Sutter General Hospital - Sacramento
- University of California At San Diego - San Diego
- UCSF-Mount Zion - San Francisco
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
- Kaiser Permanente Cancer Treatment Center - South San Francisco
- Stanford University Hospitals and Clinics - Stanford
Alabama
- The Kirklin Clinic at Acton Road - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- Arizona Oncology-Deer Valley Center - Phoenix
- Arizona Oncology Services Foundation - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2012-05 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01546987
The ClinicalTrials.gov registry entry for NCT01546987 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (61% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Radiation therapy is the first listed.
NCT01546987 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT01546987 about?
NCT01546987 is a clinical study titled "Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective...
What is the current status of trial NCT01546987?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 239 participants. The study started on 2012-05. Estimated completion is 2025-09-04.
What conditions does trial NCT01546987 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01546987?
The interventions under investigation include: Radiation therapy (RADIATION), GnRH agonist (DRUG), Anti-androgen (DRUG), TAK-700 (DRUG).
Who is sponsoring clinical trial NCT01546987?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01546987 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.